Archive | Science/Technology

Covid-19 vaccination challenges

Covid-19 vaccination challenges

Should we shame and pressure people to take the [“experimental”?] Covid vaccine?

Part 109/2021 (Contribution)

BRADES, Montserrat, February 28, 2021 – On Wednesday, February 23, Montserrat’s Chief Medical Officer Dr. Greenaway-Duberry unexpectedly appeared in our media. She announced that based on new findings, it is now recommended that the second dose of the Oxford/AstraZeneca vaccine for Covid-19 should be taken eight weeks after the first dose, as that gives a superior result to the previously recommended four-week point. This puts several questions on the table, starting with: just how experimental is the cluster of emerging Covid-19 Vaccines?

A key clue is found in a February 12, 2021, Gina Hawkins report on Military dot com, “Navy Will Make COVID-19 Vaccination Mandatory ‘As Soon as We Can:’ 3-Star Admiral” which cites Vice Admiral Andrew Lewis, U.S. Second Fleet Commander and US Defense Department Officials:

“ ‘We cannot make it mandatory yet,’ [Admiral] Lewis said. ‘I can tell you we’re probably going to make it mandatory as soon as we can, just like we do with the flu vaccine’ . . . . Defense Department officials have previously said that the COVID-19 vaccine would remain voluntary while it’s under emergency-use authorization by the Food and Drug Administration. That designation is expected to last up to two years while the FDA assesses the vaccination’s efficacy and side effects.”[1]

Taking account of testing already undertaken in recent months, this tells us that it may take up to two or three years “[to] assess . . . efficacy and side effects.” That easily explains why our CMO has had to make a change in the recommended waiting time to take our booster shots: globally, we are still studying and learning about the vaccine, the “science” has not settled down yet.

In a related Defence dot gov  report, “Military, Medical Leaders Discuss COVID-19 Issues With Service Members,” Terri Moon Cronk cites[2] US Army General and then Chairman of the Joint Chiefs of Staff, Mark A. Milley, who:

“. . . noted that the National Institutes of Health and the Food and Drug Administration have declared the vaccines as “safe and highly effective” but he acknowledged that getting the vaccine is a personal decision. “We . . .  encourage you to consult your primary care physician to address any concerns . . .  so you can be well-equipped to make the right decision for you and your family,” Milley said. “Protect yourself, protect your families and protect our communities. Together, we can all lead the way for the nation in the fight against COVID-19.”

We see here a clear recognition that while there is good evidence of vaccine effectiveness, we are responding to a global, fast-moving pandemic and are strictly speaking still in a somewhat exploratory phase of testing and evaluating the vaccines. The challenge being faced by officials here and overseas is that the epidemic is outracing the usual pace of new drug development, testing and certification so it is necessary to act on good enough but not complete evidence, in hopes of saving lives, net.

But what about the AstraZeneca vaccine in use here?

A copy of the official “Product Information as approved by the CHMP on 29 January 2021, pending endorsement by the European Commission,” tells us:

“COVID-19 Vaccine AstraZeneca is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 18 years of age and older.  The use of this vaccine should be in accordance with official recommendations . . . . The safety and efficacy of COVID-19 Vaccine AstraZeneca in children and adolescents (less than 18 years of age) have not yet been established. No data are available . . . .Appropriate medical treatment and supervision should always be readily available in case of an anaphylactic event [i.e. strong allergic reaction] following the administration of the vaccine. Close observation for at least 15 minutes is recommended following vaccination. A second dose of the vaccine should not be given to those who have experienced anaphylaxis to the first dose of COVID-19 Vaccine AstraZeneca . . . . The duration of protection afforded by the vaccine is unknown as it is still being determined by ongoing clinical trials . . . . Currently available clinical trial data do not allow an estimate of vaccine efficacy in subjects over 55 years of age.” 

In short, the AstraZeneca vaccine is also still being evaluated through “ongoing clinical trials.” It is credibly effective but clearly, points of concern remain. Therefore, we should recognise that while it is generally advisable to take it, any significant medical treatment should be taken under the advice of a doctor familiar with one’s medical history and current circumstance. That is simple, basic medical ethics and professional standards. (That’s part of why when we first go to a doctor she or he will normally take our general medical history, blood pressure etc. and will set up a patient file.)

Similarly, it is common sense that people prone to strong allergic reactions or who have significant medical challenges should be extra careful to get advice from their doctor.

Finally, what about “herd immunity”?

It is commonly reported that the AstraZeneca vaccine is about 70% effective.[3]  Where, we can see from a Healthline dot com article by Noreen Iftikhar, MD, “What Is Herd Immunity and Could It Help Prevent COVID-19?”[4] that:

“For some diseases, herd immunity can go into effect when 40 percent of the people in a population become immune to the disease, such as through vaccination. But in most cases, 80 to 95 percent of the population must be immune to the disease to stop its spread.  For example, 19 out of every 20 people must have the measles vaccination for herd immunity to go into effect and stop the disease. This means that if a child gets measles, everyone else in this population around them will most likely have been vaccinated, already have formed antibodies, and be immune to the disease to prevent it from spreading further.”

“Herd immunity” happens when on average an infected person is so unlikely to pass the disease on to someone without antibodies that it begins to “die out.”  That can come from enough people catching then recovering from a disease, or from vaccination. Now, we know that Covid-19 is fairly contagious so the 80% estimate some have suggested is reasonable. But if 100% of our population is vaccinated with a vaccine estimated to be 70% effective, then by simple Arithmetic we cannot make the 80 – 95% of population threshold; herd immunity may not be achievable using AstraZeneca, not only from “doing our sums” but especially as we can see that it is not recommended for children under 18

Where, too, the other vaccines that are said to be 90+% effective in immunising (Moderna, Pfizer), are based on novel technologies never before used with people. That means they are far more experimental than AstraZeneca.

Obviously, there is room for different opinions and for different people to make up their minds on the balance of medical risks they face given issues such as allergic reactions.


[1]           See: https://www.military.com/daily-news/2021/02/12/navy-will-make-covid-19-vaccination-mandatory-soon-we-can-3-star-admiral.html

[2]           See https://www.defense.gov/Explore/News/Article/Article/2493366/military-medical-leaders-discuss-covid-19-issues-with-service-members/

[3]           For example, see https://inews.co.uk/news/uk/covid-vaccine-how-effective-astrazeneca-pfizer-moderna-vaccination-efficacy-compared-what-meaning-845136

[4]           See https://www.healthline.com/health/herd-immunity

Posted in COVID-19, De Ole Dawg, Health, International, Local, News, Regional, Science/Technology0 Comments

New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?

New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?

New Side Effects With AstraZeneca and Janssen COVID-19 Vaccines?

TMR is not suggesting to anyone not to access COVID-19 ‘vaccines’. Merely providing information to those who may be at risk, knowingly or otherwise, to be aware that there ARE varying life-threatening risks and to consider and consult, before becoming a ‘negative/positive statistic, all the theories, conspiratorial, truths taken on board. We encourage there is not an earlier time available for everyone to take stock of their health and immunise themselves against all poor health lifestyles.

Medscape Logo
Medical Newsreprint

by Sue Hughes

April 09, 2021

Editor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center.

In addition to the unusual blood clots linked to the AstraZeneca COVID-19 vaccine, which have received extensive attention in the past couple of weeks, other safety signals are also being investigated with this vaccine, and now with Johnson & Johnson’s Janssen vaccine as well, the European Medicines Agency (EMA) reports.

Highlights of the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) meeting April 6-9 include that the agency has started a review of a safety signal to assess reports of capillary leak syndrome in people who were vaccinated with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).

It also reports that PRAC has started a review of a safety signal to assess reports of thromboembolic events with low platelets in people who received the COVID-19 Vaccine Janssen.

Capillary Leak Syndrome with AZ Vaccine

An EMA press release issued today notes that five cases of capillary leak syndrome, characterized by leakage of fluid from blood vessels causing tissue swelling and a drop in blood pressure in individuals receiving the AstraZeneca vaccine, were reported in the EudraVigilance database.

“At this stage, it is not yet clear whether there is a causal association between vaccination and the reports of capillary leak syndrome. These reports point to a ‘safety signal’ — information on new or changed adverse events that may potentially be associated with a medicine and that warrants further investigation,” the EMA states.

PRAC will evaluate all the available data to decide if a causal relationship is confirmed or not, it adds.

Thromboembolic Events with J&J/Janssen Vaccine

Four serious cases of unusual blood clots with low blood platelets have been reported postvaccination with COVID-19 Vaccine Janssen, EMA reports. One case occurred in a clinical trial and three cases occurred during the vaccine rollout in the US. One of them was fatal.

COVID-19 Vaccine Janssen is currently only used in the US, under an emergency use authorization. COVID-19 Vaccine Janssen was authorized in the EU on March 11. The vaccine rollout has not started yet in any EU member state but is expected in the next few weeks.

The Janssen vaccine uses an adenovirus vector, as does the AstraZeneca vaccine.

PRAC is investigating these cases and will decide whether regulatory action may be necessary, which usually consists of an update to the product information, it adds.

For more news, follow Medscape on Facebook, Twitter, Instagram, YouTube, and LinkedIn

Additional ‘educational’ reading: https://www.medscape.org/viewarticle/948301

Posted in Business/Economy/Banking, COVID-19, Education, International, Local, News, Opinions, Regional, Science/Technology0 Comments

Corona-virus-tidbits-19

Dr. Ryan Cole speaks, Vitamin D, Ivermectin, “Vaccines” re COVID-19

TMR research for over a year of questioning as high up to the world stage of briefings from WHO/PAHO/CARPHA, about the message to be given to COVID-19, its prevention by building immunity, and treatment that can mitigate the sufferings the virus brings; to the alternative to the suspicious and far from full protection from the experimental vaccines; brought us to this video: Vitamin D, Ivermectin, “Vaccines” https://www.bitchute.com/video/5UHDpnt6ZYrp/ – following our several Facebook posts at –https://www.facebook.com/themontserratreporter.
Dr. Ryan Cole speaking on Vitamin D, Ivermectin, “Vaccines”
Dr. Ryan Cole is the CEO and Medical Director of Cole Diagnostics, one of the largest independent labs in the State of Idaho. Dr. Cole is a Mayo Clinic-trained Board Certified Pathologist.

This summary provides:

<<The current CDC and NIH recommendation: “Go home and isolate; if you can’t breathe or your lips turn blue, then go to the hospital” (this amounts to apathy, not treatment, as physicians are trained to treat people at the first instance of a disease/pathogen).

The earlier the treatment, the more complications that can be avoided over time (simple common sense).

If there is a treatment extant for a disease, then the federal government cannot approve a vaccine [for Emergency Use Authorisation by law . . . .

Six months ago, the World Health Organization said to “stop using Remdisivir because it doesn’t add survivability to any patients” (the drug only works during the first 2-3 days of infection).

Yet, many US hospitals still administer the drug at $3,000 per dose long after initial infection when the virus has already massively replicated.

Convalescent plasma also only works during the first 2-3 days when the virus is replicating (only obtained in the hospital when the treatment is no longer effective).

Monoclonal antibodies also only work during the first couple of days with the disease.

Administering steroids at the right point in the disease (during an inflammatory state) does add survival benefit.

Ivermectin (an anti-parasitic given to horses and dogs) is an effective prevention and treatment therapy.

Although an anti-parasitic, Ivermectin also is a phenomenal anti-viral prophylaxis and can be used for early treatment, immune modifier treatment during hospitalization, and post-COVID “long hauler” treatment.

Ivermectin is safe, effective, and INEXPENSIVE, having been taken by 4 billion people since the 1980s (it is on the world’s most essential drugs list!).

In Petri dish studies conducted, in August 2020, Ivermectin was found to have killed 99% of the virus, but the NIH recommended against its use.

Ivermectin has been given in the past to humans at 30-40 times the recommended dosage with no adverse effect (only two humans have ever been determined to have died after using the drug, and they had a rare immunodeficiency disease).

A few Ivermectin studies are finally being conducted independently in the US in Texas, Florida, and Wisconsin hospitals (results: they have decreased their COVID death rates by 70-90%!).

In Houston, one hospital was using it; now, all hospitals in Houston administer the drug.

It is an approved medicine, but it is off-label (approved for other uses) because the FDA has not approved its use to treat the virus because studies haven’t been completed on Americans – the FDA doesn’t use foreign studies to approve drugs).

However, Pfizer received FDA approval for its experimental vaccine based on tests on foreign subjects, not Americans (!).

In meta-analysis of 15,000 patients, Ivermectin – if added to the treatment plan, no matter what that plan is – reduces the death rate by at least 75% (up to 86% if given early) . . .

A full course of Ivermectin treat costs under $30.

Fully 100% of the world’s Ivermectin trials have shown benefits (details provided in the video presentation):

    Decreases disease acquisition by 88-100%.

    Decreases viral replication and shedding time by half.

    Decreases disease course and severity by 80-90%.

    Decreases disease death rate by 75% and up to 86% if administered early in treatment.

Ivermectin is the only medicine that has shown benefit in 100% of world trials conducted>>

Posted in Business/Economy/Banking, COVID-19, Featured, Features, International, Local, News, Regional, Science/Technology0 Comments

logo

Progressives say Biden infrastructure bill isn’t big enough: “We can’t go back to business as usual”

logo
“This is not nearly enough,” Rep. Alexandra Ocasio-Cortez says
By Jon Skolnik
April 1, 2021 5:34PM (UTC)
main article image

Alexandria Ocasio-Cortez and Joe Biden (Photo illustration by Salon/Getty Images)

President Joe Biden proposed a $2 trillion federal spending package on Wednesday that would revamp the country’s crumbling infrastructure, taking specific aim at pollution, job creation, housing, and corporate taxes. But many on the left who have championed the Green New Deal say the president’s plan isn’t big enough. 

“This is not nearly enough,” tweeted Rep. Alexandra Ocasio-Cortez, D-N.Y, regarding the size of the bill. “The important context here is that it’s $2.25T spread out over 10 years. For context, the COVID package was $1.9T for this year *alone,* with some provisions lasting 2 years. Needs to be way bigger.

Advertisement:

“I think it’s a step towards our vision of a Green New Deal,” Ellen Sciales, a spokesperson for Sunrise Movement, echoed. “But the truth is this does not meet the scale and the scope of what we need to meet the true scale and urgency of the climate crisis.”

Sen. Sheldon Whitehouse, D-R.I., a member of the Environment and Public Works Committee, likewise called the bill a “fine starting point.”

Under Biden’s current proposal, the federal government would, among other measures, allot $621 billion to transportation infrastructures such as bridges, ports, and roads; put $580 billion toward American manufacturing, job training, and research and development; designate $400 billion to care for elderly and disabled Americans; invest $300 billion into constructing and repairing affordable housing, as well as schools; infuse the U.S. electric vehicle industry with $174 billion, and dedicate $5 billion to repair every lead pipe and service line nationally.

“These are investments we have to make,” Biden said of the bill on Wednesday. “We can afford to make them. To put it another way — we can’t afford not to.”

However, many progressive Democrats have already proposed a spate of separate bills designed to expand the bill’s scope of influence. For instance, Elizabeth Warren, D-Mass., and Rep. Andry Levin, D-Mich., introduced a bill that would subsidize the purchase of sustainable products made in America. 

The Progressive Congressional Caucus on Monday floated the Transform, Heal and Renew by Investing in a Vibrant Economy (THRIVE) Act, which calls for a $10 trillion investment in green infrastructure, renewable energy, and other climate justice measures over the next decade. The bill heavily addresses racial inequality and dedicates 40% of federal investments to minority groups that have been “excluded, oppressed and harmed by racist unjust practices.”

Advertisement:

“We are facing a series of intersecting crises,” Sen. Ed Markey, D-Mass, the bill’s co-sponsor, said. “Climate change, a public health pandemic, racial injustice and economic inequality. We can’t defeat any of these crises alone. We must develop a roadmap for recovery that addresses them all.”

An analysis conducted by the Sierra Club, an environmental nonprofit, found that the THRIVE Act would generate 15 million jobs. The bill is part of a broader push spearheaded by Interior Secretary Deb Haaland, who unveiled the THRIVE agenda when she was representative for New Mexico. According to Data for Progress, Haaland’s agenda drew broad support from Americans, especially swing voters.

Advertisement:

“We need a plan that will end the unemployment crisis, but we need this plan to also fight systemic racism, protect public health and drastically cut down on climate pollution,” Markey said. “We cannot go back to business as usual. We have a chance to truly, in this moment, to build back better and greener than ever before.” 

Jon Skolnik

Jon Skolnik is a staff writer at Salon. His work has appeared in Current Affairs, The Baffler, AlterNet, and The New York Daily News. MORE FROM Jon SkolnikFOLLOW @skolnik_jon

Posted in Business/Economy/Banking, Climate/Weather, Energy, International, Local, News, Regional, Science/Technology, Technology, TOURISM0 Comments

Spring breakers flock to Florida beaches

‘Impending doom’: Why the US is facing a new coronavirus wave despite one of the world’s best vaccine programmes

Reprint

By Jamie Johnson, US correspondent, Washington 30 March 2021

Hospitalisations are increasing and deaths are multiplying from the disease that has already killed 550,000 people in the US By Jamie Johnson, US correspondent, Washington 30 March 2021

Joe Biden, the US President, has urged states to pause their reopening efforts after a senior health official warned of the “impending doom” of a deadly third wave of coronavirus cases.

Despite a hugely successful vaccine programme – one in six Americans is already fully inoculated – cases are rising, hospitalisations are increasing, and deaths are multiplying from the disease that has already killed 550,000 people in the United States.

“We still are in a war with this deadly virus and we’re bolstering our defences. But this war is far from won,” said Mr Biden.

Dr Rochelle Walensky, the director of the US public health agency, the Centres for Disease Control and Prevention (CDC), appeared to fight back tears on Thursday as she said: “I’m going to reflect on the recurring feeling I have of impending doom.

“We have so much reason for hope, but right now I’m scared”.

As Boris Johnson warns that a third wave in the UK is still a risk, despite a successful vaccine programme, the US may be used as a barometer for how the situation in Britain could evolve.

How is the US vaccine rollout programme progressing?

While his administration ramps up its drive to administer jabs as quickly as possible, Mr Biden has said that 90 per cent of US adults would be eligible for vaccination by April 19, and 90 per cent of Americans would have a vaccination centre within five miles of their homes by then.

So far, 145,812,835 vaccine doses have been administered and 15.8 per cent of Americans are fully vaccinated.

On Monday, Texas, Kansas, Louisiana, North Dakota, Ohio and Oklahoma made all adults eligible for vaccination. New York said that all adults would be eligible starting April 6.

Mr Biden had pledged to administer 100 million vaccine shots in his first 100 days in office. That goal has since been revised to 200 million after the first was met within 60 days.

With more than 2.5 million jabs a day, it is widely accepted that the rollout is going well.

What is going wrong?

The number of new coronavirus cases jumped by seven per cent over the past week to a seven-day average of around 60,000 cases, according to the CDC.

Data from the New York Times shows that in nine states over the past two weeks, virus cases have risen more than 40 per cent.

Connecticut reported a 62 per cent jump over the past two weeks, and New York and Pennsylvania both reported increases of more than 40 percent.

Michigan saw a 133 per cent increase – and epidemiologists have pointed to indoor dining restarting on February 1 as being a possible root cause.

In Florida, which has started welcoming tourists, the situation is worsening.

Spring Breakers were forced to be inside by 8pm as the young partygoers appeared to give up on social distancing and mask-wearing in Miami during the holidays.

In Orange County, Orlando, the average age for new infections has dropped to 30 and one in three people hospitalised is under 45.

Spring breakers flock to Florida beaches
Spring Breakers were forced to be inside by 8 pm Credit: REUTERS

But there is a wider problem at play.

Over the past week, the state has averaged nearly 5,000 cases per day, an increase of 8 per cent from its average two weeks earlier.

Worryingly for the UK, the Kent strain is also rising exponentially in Florida, where it accounts for a greater proportion of total cases than in any other state, according to the CDC.

Case Study: Texas

Fewer restrictions do not automatically mean more cases, data from Texas appears to show.

In a controversial move on March 2, Governor Greg Abbott ended the state’s restrictions despite Texas recording about as many cases per day as the UK on average and having a population less than half the size.

“I just announced Texas is OPEN 100%. EVERYTHING. I also ended the statewide mask mandate.”

Mr Biden called it “irresponsible”

But the latest figures show that they may have got it right. According to New York Times data, over the past two weeks coronavirus infections in Texas have declined 17 per cent, deaths have declined 34 per cent and hospitalisations have declined 25 per cent.

One note of caution, however, is that the seven-day average of newly reported coronavirus infections was up on Sunday to 3,774. Last Wednesday, the average case count was at a low of 3,401.

What is being done to stop the spread?

The speedy vaccine operation is not moving fast enough to stop the spread of the virus and the President has criticised the “neanderthal thinking” of some state governors who have dropped the requirements for people to wear masks.

“The failure to take this virus seriously is precisely what got us into this mess in the first place,” said Mr Biden.

“I’m reiterating my call for every governor, mayor and local leader to maintain and reinstate the mask mandate.

Asked if states should pause re-opening efforts, Mr Biden said “yes.”

It is yet to be seen if the states will listen.

Mr. Biden has got off to a strong start and is polling well because he has tackled the two most pressing issues for Americans head-on – the economy and the pandemic.

A $1.9 trillion (with a T) relief package has seen cheques for $1,400 sent to the vast majority of households to help cover lost income and pay the bills, while the vaccine programme is moving at a pace.

Much as in the UK, American health officials have told the public to “stick with it.”

“I know you all so badly want to be done,” said Dr Walensky. “We are just almost there, but not quite yet.”

What could the UK learn?

The US has not had a slow-release – each state taking forging its own path out of lockdown. That is why the data looks different in some areas. But of those where public spaces are opened, the general correlation is that cases have again risen.

“Because the government has allowed some things to open up, people have viewed that as a good thing to do,” Dawn Misra, a professor of epidemiology and biostatistics at Michigan State University told the New York Times.

“This is a really tricky part of public health messaging. Just because you’re allowed to be in restaurants and other places do not mean they are safe.”

This should give the UK pause for thought.

In the UK, things are moving in the right direction. Sunday had the lowest number of newly recorded cases in six months, while there were no Covid-related deaths in the capital.

But the prospect of continued success may not remain in the Prime Minister’s hands.

A third wave

Boris Johnson said that Britain needs to “build our defences” against a third wave brewing in Europe for “when it comes” to the UK.

“What we don’t know is exactly how strong our fortifications now are, how robust our defences are against another wave,” he said, ominously.

Europe is struggling with the vaccine rollout, and cases are rising again.

Paris and parts of northern and southern France are one week into a lockdown which will last at least four weeks, in an attempt to stem a third Covid wave fuelled by contagious variants.

Italy and Germany have tightened their borders.

In the US, a third wave is also bubbling under the surface, as explained by the number of rising cases, even in states where masks and social restrictions are still stringent.

As restrictions lift the UK and the US will be relying on their vaccine programmes outrunning the new variants. Whether they can remains to be seen.

Joe Biden finished his press conference on Monday by saying: “Fight to the finish. Don’t let up now.”

In a tweet on Tuesday, Mr Johnson said: “The vaccine is our best route out of this pandemic and we must all do our part by taking the vaccine when it is offered to us.”

Major Israeli study finds Pfizer jab 94 percent effective in ‘real world’ use
https://www.telegraph.co.uk/global-health/science-and-disease/major-israeli-study-finds-pfizer-jab-94-per-cent-effective-real/

Posted in COVID-19, Health, International, Local, News, Politics, Regional, Science/Technology0 Comments

Senators come together to make daylight saving time permanent

Senators come together to make daylight saving time permanent

Reprint

Sarah K. Burris – March 09, 2021

Senators come together to make daylight saving time permanent

Marco Rubio (MSNBC/Screenshot)

Year after year, particularly in the spring and fall Americans lament Daylight Saving Time, an antiquated way of adjusting the time to help preserve as much light as possible. Many believe it was due to the U.S. agrarian society, but according to the History Channel’s factoids, the agriculture industry actually opposed it.

Germany was the first country to implement the idea on April 30, 1916, and the U.S. first did it in 1918, with Congress attempting to repeal it in 1919.

“Rather than rural interests, it has been urban entities such as retail outlets and recreational businesses that have championed daylight saving over the decades,” said History.com. Tired of ads? Want to support our progressive journalism? Click to learn more.

Sens. Marco Rubio (R-FL), James Lankford (R-OK), Roy Blunt (R-MO), Sheldon Whitehouse (D-RI), Ron Wyden (D-OR), Cindy Hide-Smith (R-MS), Rick Scott (R-FL), and Ed Markey (D-MA) are all endorsing the Sunshine Protection Act, according to a release. Fifteen states have changed their Daylight Saving Time rules and dozens more are also considering doing it. States include Arkansas, Alabama, California, Delaware, Georgia, Idaho, Louisiana, Maine, Ohio, Oregon, South Carolina, Tennessee, Utah, Washington, and Wyoming.

The time was once isolated to just a few states, but now that there are more states it can create more confusion. The growing list of states is causing more problems as Americans start traveling again and have no idea whether a state is observing the time change or not.

See the release below:

Image

Posted in Business/Economy/Banking, Climate/Weather, Climate/Weather, Culture, Environment, International, Local, News, Regional, Science/Technology0 Comments

Coronavirus vaccine – weekly summary of Yellow Card reporting

Severe Allergy

This advice is that people with a previous history of severe allergic reactions to any ingredients of the vaccine should not receive it. People who receive the vaccine should be monitored for at least 15 minutes afterwards.

The foregoing is taken from the UK Government web site on COVID-19 https://www.gov.uk/government/publications/coronavirus-covid-19-vaccine-adverse-reactions/coronavirus-vaccine-summary-of-yellow-card-reporting

See below the summary of the full version of the above link.

Summary

At the time of this report, more than 120,000 people across the UK have died within 28 days of a positive test for coronavirus (COVID-19). Rates of COVID-19 infection and hospitalisation remain high.

Vaccination is the single most effective way to reduce deaths and severe illness from COVID-19. A national immunisation campaign has been underway since early December 2020.

Two COVID-19 vaccines, Pfizer/BioNTech and Oxford University/AstraZeneca vaccines, are currently being used in the UK. Both have been authorised for supply by the Medicines and Healthcare products Regulatory Agency (MHRA) following a thorough review of safety, quality, and efficacy information from clinical trials. In clinical trials, both vaccines showed very high levels of protection against symptomatic infections with COVID-19. We expect data to be available soon on the impact of the vaccination campaign in reducing infections and illness in the UK.

All vaccines and medicines have some side effects. These side effects need to be continuously balanced against the expected benefits in preventing illness.

The Pfizer/BioNTech vaccine was evaluated in clinical trials involving more than 44,000 participants. The most frequent adverse reactions in trials were pain at the injection site, fatigue, headache, myalgia (muscle pains), chills, arthralgia (joint pains), and fever; these were each reported in more than 1 in 10 people. These reactions were usually mild or moderate in intensity and resolved within a few days after vaccination. Adverse reactions were reported less frequently in older adults (over 55 years) than in younger people.

The Oxford University/AstraZeneca vaccine was evaluated in clinical trials involving more than 23,000 participants. The most frequently reported adverse reactions in these trials were injection-site tenderness, injection-site pain, headache, fatigue, myalgia, malaise, pyrexia (fever), chills, arthralgia, and nausea; these were each reported in more than 1 in 10 people. The majority of adverse reactions were mild to moderate in severity and usually resolved within a few days of vaccination. Adverse reactions reported after the second dose were milder and reported less frequently than after the first dose. Adverse reactions were generally milder and reported less frequently in older adults (65 years and older) than in younger people.

The MHRA’s role is also to continually monitor safety during widespread use of a vaccine. We have in place a proactive strategy to do this. We also work closely with our public health partners in reviewing the effectiveness and impact of the vaccines to ensure the benefits continue to outweigh any possible side effects.

Part of our monitoring role includes reviewing reports of suspected side effects. Any member of the public or health professional can submit suspected side effects through the Yellow Card scheme. The nature of Yellow Card reporting means that reported events are not always proven side effects. Some events may have happened anyway, regardless of vaccination. This is particularly the case when millions of people are vaccinated, and especially when most vaccines are being given to the most elderly people and people who have underlying illness.

This safety update report is based on detailed analysis of data up to 14 February 2021. At this date, an estimated 8.3 million first doses of the Pfizer/BioNTech vaccine and 6.9 million doses of the Oxford University/AstraZeneca vaccine had been administered, and around 0.6 million second doses, mostly the Pfizer/BioNTech vaccine, had been administered. This represents an increase of 2.8 million on the previous week.

As of 14 February 2021, for the UK

  • 26,823 Yellow Cards have been reported for the Pfizer/BioNTech
  • 31,427 have been reported for the Oxford University/AstraZeneca vaccine
  • 177 have been reported where the brand of the vaccine was not specified

For both vaccines, the overall reporting rate is around 3 to 5 Yellow Cards per 1,000 doses administered.

In the week since the previous summary for 7 February 2021, we have received a further 2,616 Yellow Cards for the Pfizer/BioNTech vaccine, 10,999 for the Oxford University/AstraZeneca vaccine, and 64 where the brand was not specified. A higher number of doses of the Oxford University/AstraZeneca vaccine were administered in the last week than the Pfizer/BioNTech vaccine.

For both vaccines, the overwhelming majority of reports relate to injection-site reactions (sore arm for example) and generalised symptoms such as ‘flu-like’ illness, headache, chills, fatigue (tiredness), nausea (feeling sick), fever, dizziness, weakness, aching muscles, and rapid heartbeat. Generally, these happen shortly after the vaccination and are not associated with more serious or lasting illness.

These types of reactions reflect the normal immune response triggered by the body to the vaccines. They are typically seen with most types of vaccines and tend to resolve within a day or two. The nature of reported suspected side effects is broadly similar across age groups, although, as was seen in clinical trials and as is usually seen with other vaccines, they may be reported more frequently in younger adults.

Severe allergy

On 9 December 2020, the MHRA issued preliminary guidance on severe allergic reactions after the Pfizer/BioNTech vaccine due to early reports of anaphylaxis. Following a further detailed review, this advice was amended on 30 December to the current advice. This advice is that people with a previous history of severe allergic reactions to any ingredients of the vaccine should not receive it. People who receive the vaccine should be monitored for at least 15 minutes afterwards.

Widespread use of the vaccine now suggests that severe allergic reactions to the Pfizer/BioNTech vaccine are very rare. Anaphylaxis can also be a very rare side effect associated with most other vaccines.

Following very substantial exposure across the UK population, no other new safety concerns have been identified from reports received so far.

Conclusion

  • The increases in the number of ADR reports reflects the increase in vaccine deployment as new vaccination centres have opened across the UK
  • The number and nature of suspected adverse reactions reported so far are not unusual in comparison to other types of routinely used vaccines
  • The overall safety experience with both vaccines is so far as expected from the clinical trials
  • Based on current experience, the expected benefits of both COVID-19 vaccines in preventing COVID-19 and its serious complications far outweigh any known side effects
  • As with all vaccines and medicines, the safety of COVID-19 vaccines is being continuously monitored

Further information on the type of suspected adverse reactions (ADRs) reported for the COVID-19 mRNA Pfizer/BioNTech vaccine and the COVID-19 Vaccine AstraZeneca is provided in Annex 1. It is important to read the guidance notes to ensure appropriate interpretation of the data.

Posted in Business/Economy/Banking, COVID-19, Culture, Education, Featured, Features, Health, International, Local, News, Regional, Science/Technology0 Comments

Natural-News-logo

UK government reports over 240 deaths shortly after coronavirus vaccination

by: Ramon Tomey – February 24, 2021

Tags: AstraZeneca, badhealth, badmedicine, badscience, Big Pharma, BioNTech, coronavirus vaccine, covid-19 pandemic, Medicines and Healthcare products Regulatory Agency, Pfizer, United Kingdom, Vaccine deaths, vaccine injury, vaccine safety, vaccine wars, Wuhan coronavirus, Yellow Card reports

Image: UK government reports over 240 deaths shortly after coronavirus vaccination

(Natural News) The U.K. government reported that more than 240 people have died shortly after getting the Wuhan coronavirus vaccines. British citizens who died after vaccination reportedly obtained either the Pfizer/BioNTech vaccine or the AstraZeneca jab. These vaccine candidates were approved by the British regulator and subsequently used in mass vaccination efforts. Despite this, the U.K. government said it does not believe that the inoculations are to blame for the deaths.

In an extensive report released on Feb. 11, the U.K. government detailed all the adverse reactions reported by both medical personnel and COVID-19 vaccine recipients themselves. The report’s scope included all cases between early December 2020 and the end of January 2021.

According to the release, the Medicines and Healthcare Products Regulatory Agency (MHRA) received 143 adverse reaction reports attributed to the Pfizer/BioNTech jab. The AstraZeneca vaccine made in partnership with the University of Oxford reported 90 adverse reactions. There were three reactions where the vaccine brand was not mentioned. Furthermore, a total of eight miscarriages were reported following COVID-19 vaccination – five for the Pfizer/BioNTech vaccine and three for the AstraZeneca candidate.

To further monitor vaccine safety alongside mass immunization efforts, the MHRA introduced a Yellow Card Scheme to collect reports of any suspected side effects. More than 20,000 Yellow Card reports were linked to the Pfizer/BioNTech vaccine. On the other hand, the AstraZeneca jab rolled out last Jan. 4 had 11,748 Yellow Card reports. Seventy-two Yellow Card reports did not specify the brand of the vaccine.

Elderly people or those with underlying conditions made up the majority of the reports. However, the government said either of the vaccines did not play a role in the fatalities based on a review of individual reports and reporting patterns.

The report mentioned that for both vaccines, an overwhelming majority reported reactions at the injection site such as sore arms and generalized symptoms. These generalized symptoms included headache, chills, fatigue, fever, dizziness, and muscle aches. These happen shortly following the vaccination and are not associated with more serious illnesses. However, “spontaneous adverse reactions associated with anaphylaxis or anaphylactoid reactions” were also reported – 130 for the Pfizer/BioNTech vaccine and 30 for the AstraZeneca jab.

Pfizer/BioNTech jab linked to vaccination deaths in other countries

According to the report, more than 9.2 million first doses of the COVID-19 vaccines have been administered in the U.K.’s four constituent countries. Meanwhile, 494,209-second doses have been administered in the four areas. (Related: UK to deploy “resuscitation facilities” in coronavirus vaccination centers to treat wave of allergic reactions caused by vaccines.)

The U.K. is not the only country that has reported fatalities following COVID-19 vaccination. A number of medical personnel also died after getting vaccinated against the Wuhan coronavirus – most notably with the Pfizer/BioNTech vaccine.

Florida obstetrician Dr. Gregory Michael died in January after getting inoculated with the first Pfizer/BioNTech COVID-19 vaccine dose. The 56-year-old received his first dose on Dec. 18, but small spots appeared on his hands and feet three days after immunization. He then visited the emergency room of his workplace, Mount Sinai Medical Center, where he was confined. Doctors then found out that the obstetrician had zero blood platelets.

Despite undergoing transfusions to restore his platelet count, it did little for Michael. He eventually suffered a stroke and died as he was set to undergo a last-minute surgical procedure. Michael’s wife Heidi Neckelmann said: “In my mind, his death was 100 percent linked to the vaccine. There is no other explanation.”

Meanwhile, in Portugal, health worker Sonia Acevedo died just a mere two days after getting the COVID-19 jab. The 41-year-old mother of two who worked at the Portuguese Institute of Oncology (IPO) in Porto did not report any adverse effects after immunization. Acevedo was among more than 500 Porto IPO staff who were vaccinated against COVID-19 using the Pfizer/BioNTech vaccine.

Sonia’s father Abilio Acevedo said his daughter “was okay” and had no health problems. “She had the COVID-19 vaccine, but she didn’t have any symptoms,” he remarked. Abilio continued that he and his daughter even ate together on New Year’s Eve, not knowing that it would be the last time he would see her alive. He subsequently received a call informing him that Sonia was found dead the morning of Jan. 1. “My daughter left home and I never saw her alive again,” he lamented.

Sonia’s daughter Vania Figueredo meanwhile said that her mother had only complained about the “normal” discomfort in the injection site. Figueredo added that aside from this complaint, her mother felt fine. (Related: Nurse aide dies after receiving work-mandated coronavirus vaccine shot.)

Visit VaccineDeaths.com to find out more news about fatalities caused by the Wuhan coronavirus jabs.

Sources include:

LifeSiteNews.com; Gov.uk; DailyMail.co.uk 1; DailyMail.co.uk 2

Posted in Business/Economy/Banking, COVID-19, Featured, Features, Health, International, Local, News, Regional, Science/Technology0 Comments

See what you can find on our Facebook Page

See what you can find on our Facebook Page

https://www.facebook.com/themontserratreporter?comment_id=Y29tbWVudDoxMDE1ODA3MjY5MjUxNTg1Ml8xMDE1ODA3NDQ1MjQwMDg1Mg%3D%3D

See what some of our Facebook readers benefit – Do Zinc and Vitamin C Reduce COVID Symptoms?

https://www.medscape.com/viewarticle/945794

COVID-19 maps
https://www.univadis.co.uk/covid-19-map?utm_source=medscape&utm_medium=partners&utm_campaign=covid19map&ecd=ban_mscp_covidmap_unicovid_link_mapUK

THE TRUTH, THE LIES, AND THE MISCONCEPTIONS

FINALLY, YOUR ANSWERS FOR WHAT’S REALLY GOING ON WITH COVID, THE PANDEMIC, AND THE “VACCINE”.


https://vrevealed.com/covid/own/

https://youtu.be/J531bU0OYuc
Boosting the Immune System

If this can be followed from the beginning it is recommended for all to follow as it is undoubtedly important that our authorities be responsible to share the information re the ‘vaccines’ to satisfy those who do not know why and how they should accept the COVID-19 ‘vaccine’
https://youtu.be/BG-auqdR8m4

Posted in COVID-19, Featured, International, Local, News, Regional, Science/Technology0 Comments

AP-logo

India’s dramatic fall in virus cases leaves experts stumped

Reprint

By KRUTIKA PATHI and ANIRUDDHA GHOSAL, Associated Press – Associated Press – 16 February 2021

NEW DELHI (AP) — When the coronavirus pandemic took hold in India, there were fears it would sink the fragile health system of the world’s second-most populous country. Infections climbed dramatically for months and at one point India looked like it might overtake the United States as the country with the highest case toll.

But infections began to plummet in September, and now the country is reporting about 11,000 new cases a day, compared to a peak of nearly 100,000, leaving experts perplexed.

They have suggested many possible explanations for the sudden drop — seen in almost every region — including that some areas of the country may have reached herd immunity or that Indians may have some preexisting protection from the virus.

The Indian government has also partly attributed the dip in cases to mask-wearing, which is mandatory in public in India and violations draw hefty fines in some cities. But experts have noted the situation is more complicated since the decline is uniform even though mask compliance is flagging in some areas.

It’s more than just an intriguing puzzle; determining what’s behind the drop in infections could help authorities control the virus in the country, which has reported nearly 11 million cases and over 155,000 deaths. Some 2.4 million people have died worldwide.

“If we don’t know the reason, you could unknowingly be doing things that could lead to a flare-up,” said Dr. Shahid Jameel, who studies viruses at India’s Ashoka University.

India, like other countries, misses many infections, and there are questions about how it’s counting virus deaths. But the strain on the country’s hospitals has also declined in recent weeks, a further indication the virus’s spread is slowing. When recorded cases crossed 9 million in November, official figures showed nearly 90% of all critical care beds with ventilators in New Delhi were full. On Thursday, 16% of these beds were occupied.

That success can’t be attributed to vaccinations since India only began administering shots in January — but as more people get a vaccine, the outlook should look even better, though experts are also concerned about variants identified in many countries that appear to be more contagious and render some treatments and vaccines less effective.

Among the possible explanations for the fall in cases is that some large areas have reached herd immunity — the threshold at which enough people have developed immunity to the virus, by falling sick or being vaccinated, that the spread begins to slacken, said Vineeta Bal, who studies immune systems at India’s National Institute of Immunology.

But experts have cautioned that even if herd immunity in some places is partially responsible for the decline, the population as a whole remains vulnerable — and must continue to take precautions.

This is especially true because new research suggests that people who got sick with one form of the virus may be able to get infected again with a new version. Bal, for instance, pointed to a recent survey in Manaus, Brazil, that estimated that over 75% of people there had antibodies for the virus in October — before cases surged again in January.

“I don’t think anyone has the final answer,” she said.

And, in India, the data is not as dramatic. A nationwide screening for antibodies by Indian health agencies estimated that about 270 million, or one in five Indians, had been infected by the virus before vaccinations started — that’s far below the rate of 70% or higher than experts say might be the threshold for the coronavirus, though even that is not certain.

“The message is that a large proportion of the population remains vulnerable,” said Dr. Balram Bhargava, who heads India’s premier medical research body, the Indian Council of Medical Research.

But the survey offered other insight into why India’s infections might be falling. It showed that more people had been infected in India’s cities than in its villages and that the virus was moving more slowly through the rural hinterland.

“Rural areas have lesser crowd density, people work in open spaces more and homes are much more ventilated,” said Dr. K. Srinath Reddy, president of the Public Health Foundation of India.

If some urban areas are moving closer to herd immunity — wherever that threshold lies — and are also limiting transmission through masks and physical distancing and thus are seeing falling cases, then maybe the low speed at which the virus is passing through rural India can help explain sinking numbers, suggested Reddy.

Another possibility is that many Indians are exposed to a variety of diseases throughout their lives — cholera, typhoid, and tuberculosis, for instance, are prevalent — and this exposure can prime the body to mount a stronger, initial immune response to a new virus.

“If the COVID virus can be controlled in the nose and throat, before it reaches the lungs, it doesn’t become as serious. Innate immunity works at this level, by trying to reduce the viral infection and stop it from getting to the lungs,” said Jameel, of Ashoka University.

Despite the good news in India, the rise of new variants has added another challenge to efforts here and around the globe to bring the pandemic under control. Scientists have identified several variants in India, including some that have been blamed for causing new infections in people who already had an earlier version of the virus. But they are still studying the public health implications.

Experts are considering if variants may be driving a surge in cases in the southern state of Kerala, which had previously been hailed as a blueprint for tackling the virus. Kerala now accounts for nearly half of India’s current COVID-19 cases. Government-funded research has suggested that a more contagious version of the virus could be at play, and efforts to sequence its genome are ongoing.

With the reasons behind India’s success unclear, experts are concerned that people will let down their guard. Large parts of India have already returned to normal life. In many cities, markets are heaving, roads are crowded and restaurants nearly full.

“With the reducing numbers, I feel that the worst of COVID is over,” said M. B. Ravikumar, an architect who was hospitalized last year and recovered. “And we can all breathe a sigh of relief.”

Maybe not yet, said Jishnu Das, a health economist at Georgetown University who advises the West Bengal state on handling the pandemic.

“We don’t know if this will come back after three to four months,” he warned.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.

Posted in COVID-19, Health, International, Local, News, Regional, Science/Technology0 Comments

Please Support The Montserrat Reporter

This is bottom line for us! Unless we receive your support, our effort will not be able to continue. Whatever and however you can, please support The Montserrat Reporter in whatever amount you can (and whatever frequency) – and it only takes a minute.
Thank you

TMR print pages

East Caribbean Central Bank – Career Vacancies

Newsletter

Archives

FLOW - Back to School

https://indd.adobe.com/embed/2b4deb22-cf03-4509-9bbd-938c7e8ecc7d